Gary Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter & Gamble Pharmaceuticals, Warner Chilcott Pharmaceuticals and most recently Actavis. Throughout his pharmaceutical career he has been responsible for commercializing pharmaceutical products.
CEO – Gary Rojewski
LATEST ENZYME BIOSYSTEMS PRESS RELEASE & NEWS
CHAGRIN FALLS, Ohio, May 23, 2014 /PRNewswire/ — EnzymeBioSystems (ENZB) (ENZB), announces the appointment of Gary Rojewski as its new CEO, effective June 2, 2014. Mr. Rojewski will be responsible for leading and managing EnzymeBioSystems’ business operations, including regulatory affairs with government agencies.
Mr. Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter and Gamble Pharmaceuticals (PG), Warner Chilcott Pharmaceuticals, Inc. (WCRX) and most recently, Actavis (ACT). Throughout his pharmaceutical career, he has been responsible for commercializing pharmaceutical products.
“We are very happy that Gary has joined EnzymeBioSystems to lead our operations. His expertise in the pharmaceutical industry is a great fit for our business strategy,” said Anushavan Yeranosyan, Chief Accounting Officer.
Commenting on his new role, Mr. Rojewski said: “I am pleased to be joining EnzymeBioSystems at such an exciting time for the Company. My first goal is to help the Company position itself with the products under development. I plan to deliver and utilize my resources to move the Company forward.”
EnzymeBioSystems manufactures specialty enzymes and enzyme related products. We plan to use enzyme technologies to develop commercial solutions for a broad range of applications within the pharmaceutical industry. http://enzymebiosystems.org/
Included in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company’s actual results could differ materially from those anticipated in the forward-looking statements.